Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy.

Font Standard Bold
Login

Project search
Actual Project
Recent projects
Graphics
Login

Research unit

INNOSUISSE

Project number

12391.1;5 PFLS-LS

Project title

Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy.

Basic data
Texts
Participants

Texts for this project

	German	French	Italian	English
Short description	-	-	-
Abstract	-	-	-

Inserted texts

Category	Text
Short description (English)	Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy
Abstract (English)	Notch is a transmembrane receptor playing a key role in cancer. Previous work at EPFL in partnership with Debiopharm has led to the development of two bioassays to identify inhibitors of the Notch pathway. EPFL, Debiopharm & Atheris have completed a CTI funded project (10917.1 PFLS-LS) to screen selected libraries in the two bioassays resulting in the identification of several novel Notch pathway inhibitory peptides. This project aims to optimize and validate (in in vitro and animal models) these peptides for further pharmaceutical development.

Category

Text

Short description
(English)

Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy

Abstract
(English)

Notch is a transmembrane receptor playing a key role in cancer. Previous work at EPFL in partnership with Debiopharm has led to the development of two bioassays to identify inhibitors of the Notch pathway. EPFL, Debiopharm & Atheris have completed a CTI funded project (10917.1 PFLS-LS) to screen selected libraries in the two bioassays resulting in the identification of several novel Notch pathway inhibitory peptides. This project aims to optimize and validate (in in vitro and animal models) these peptides for further pharmaceutical development.